The New York Times Company Declares Regular Quarterly Dividend

The New York Times Company Declares Regular Quarterly Dividend

NEW YORK–(BUSINESS WIRE)–
The New York Times Company’s Board of Directors today declared a regular quarterly dividend of $.06 per share on the Company’s Class A and Class B common stock. The dividend is payable on January 21, 2021, to shareholders of record as of the close of business on January 6, 2021.

The New York Times Company (NYSE: NYT) is a global media organization dedicated to enhancing society by creating, collecting and distributing high-quality news and information. The Company includes The New York Times, NYTimes.com and related properties. It is known globally for excellence in its journalism, and innovation in its print and digital storytelling and its business model. Follow news about the company at @NYTimesPR.

This press release can be downloaded from www.nytco.com

Investors: Harlan Toplitzky, 212-556-7775, [email protected]

Media: Danielle Rhoades Ha, 212-556-8719, [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Advertising Communications Publishing Public Relations/Investor Relations

MEDIA:

Logo
Logo

Novo Receives Conditional Approval to Graduate to the Toronto Stock Exchange

VANCOUVER, British Columbia, Dec. 17, 2020 (GLOBE NEWSWIRE) — Novo Resources Corp. (“Novo” or the “Company”) (TSX-V: NVO & NVO.WT; OTCQX: NSRPF) is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to graduate from the TSX Venture Exchange (the “TSXV”) and list its common shares and certain common share purchase warrants (the “Warrants”) on the TSX.

Final approval of the listing is subject to the Company fulfilling the TSX’s standard listing conditions. Upon, and subject to, receipt of final TSX approval, Novo’s common shares and Warrants would be delisted from the TSXV and begin trading on the TSX under the symbols “NVO” and “NVO.WT”, respectively.

The Company’s common shares will continue to be listed on the OTCQX under the symbol “NSRPF”.

“This is a significant milestone for the Company,” commented Dr. Quinton Hennigh, Chairman, President, and a director of Novo. “Novo has grown dramatically since the Company’s initial public offering and listing on the Canadian Securities Exchange in June, 2010. I would like to thank the TSXV for its years of continuous support after accepting Novo’s listing in May 2015. Given Novo’s international exposure, we believe it is time to graduate to the TSX, one of the premier exchanges for publicly traded companies, in order to enhance liquidity of Novo’s stock and extend Novo’s appeal to the international investment community.”

About Novo Resources Corp.

Novo is advancing its flagship Beatons Creek gold project to production while exploring and developing its highly prospective land package covering approximately 14,000 square kilometres in the Pilbara region of Western Australia. In addition to the Company’s primary focus, Novo seeks to leverage its internal geological expertise to deliver value-accretive opportunities to its shareholders. For more information, please contact Leo Karabelas at (416) 543-3120 or e-mail [email protected]

On Behalf of the Board of Directors,

Novo Resources Corp.



Quinton Hennigh

                        

Quinton Hennigh

Chairman and President

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward-looking information

Some statements in this news release contain forward-looking information (within the meaning of Canadian securities legislation) including, without limitation, the anticipated receipt of final approval to the Company’s listing on the TSX and the expected resulting enhancement of liquidity of Novo’s stock and appeal to the international investment community. Forward-looking statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, without limitation, the Company’s satisfaction of the applicable conditions to listing and the TSX’s provision of final approval.



Nortech Systems Announces Establishment of Two 10b5-1 Trading Plans

Nortech Systems Announces Establishment of Two 10b5-1 Trading Plans

MINNEAPOLIS–(BUSINESS WIRE)–
Nortech Systems Incorporated (Nasdaq: NSYS), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical, aerospace & defense and industrial markets, announced today that Chairman David Kunin and Chief Financial Officer Christopher Jones have each adopted a prearranged trading plan under Rule 10b5-1 of the Securities exchange Act of 1934 to purchase shares of Nortech’s common stock on the open market. Rule 10b5-1 permits officers and directors of public companies to adopt predetermined plans for purchasing or selling specified amounts or value of stock.

Nortech’s chairman of the board, David Kunin, has established a Rule 10b5-1 trading plan to purchase shares of Nortech common stock on the open market in an amount up to $250,000 through January 2022.

In addition, Nortech’s chief financial officer, Christopher Jones, has established a Rule 10b5-1 trading plan to purchase 25,000 shares of Nortech common stock on the open market through March 31, 2021.

Nortech specializes in complex cable harnesses, printed circuit board assemblies (PCBAs) and box builds for low-volume, high-mix global engineering development and manufacturing. Nortech’s 30-year history and rapidly growing expertise in digital connectivity and data management helps its customers stay competitive today and well into the future.

Nortech uses intelligence, innovation, speed, and global expertise provide high-quality, high performance engineering and manufacturing solutions to resolve our customers’ most important challenges to be leaders in secure, reliable digital connectivity & data management. Nortech strives to be a premier workplace that fosters valued relationships internally and in our communities.

About Nortech Systems Incorporated Nortech Systems is a leading provider of design and manufacturing solutions for complex electromedical devices, electromechanical systems, assemblies, and components. Nortech Systems primarily serves the medical, aerospace & defense, and industrial markets. Its design services span concept development to commercial design, and include medical device, software, electrical, mechanical, and biomedical engineering. Its manufacturing and supply chain capabilities are vertically integrated around wire/cable/interconnect assemblies, printed circuit board assemblies, as well as system-level assembly, integration, and final test. Headquartered in Maple Grove, Minn., Nortech currently has six manufacturing locations and design centers across the U.S., Latin America, and Asia. Nortech Systems is traded on the NASDAQ Stock Market under the symbol NSYS. Nortech’s website is www.nortechsys.com.

Christopher D. Jones, Chief Financial Officer

[email protected]

952-345-2244

Cathy Vold, Senior Director of Marketing and Program Management

[email protected]

952-345-2244

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Electronic Design Automation Engineering Semiconductor Technology Manufacturing Other Manufacturing Hardware

MEDIA:

Logo
Logo

Skyharbour Closes $1.46 Million Private Placement of Flow-Through Units

VANCOUVER, British Columbia, Dec. 17, 2020 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQB: SYHBF) (Frankfurt: SC1P) (the “Company”) announces that it has closed a non-brokered private placement financing for total gross proceeds of CAD $1,461,640.32 (the “Private Placement”). The majority of the Private Placement was subscribed for by a strategic institutional investor.

The Company has allotted and issued 6,090,168 units (the “Units”) at a price of CAD $0.24 per Unit. Each Unit is comprised of one flow-through common share and one-half of one warrant (each whole, a “Warrant”). Each Warrant will entitle the holder to purchase one non-flow through common share for a period of three (3) years at a price of CAD $0.35 per share. 

In addition, the Company has paid finder’s fees of $70,000 and issued 291,667 finder’s warrants (the “Finders Warrants”) to Red Cloud Securities Inc., an arm’s-length party. Each Finders Warrant is exercisable into one common share for a period of up to three (3) years at a price of CAD $0.24.

The Company intends to use the proceeds from this Private Placement for exploration and upcoming drilling programs. The Private Placement is subject to final TSX Venture Exchange (“Exchange”) approval and all securities issued are subject to a four-month-and-one-day hold period.

About Skyharbour Resources Ltd.:

Skyharbour holds an extensive portfolio of uranium and thorium exploration projects in Canada’s Athabasca Basin and is well positioned to benefit from improving uranium market fundamentals with six drill-ready projects. Skyharbour has acquired from Denison Mines, a large strategic shareholder of the Company, a 100% interest in the Moore Uranium Project which is located 15 kilometres east of Denison’s Wheeler River project and 39 kilometres south of Cameco’s McArthur River uranium mine. Moore is an advanced stage uranium exploration property with high grade uranium mineralization at the Maverick Zone with drill results returning up to 6.0% U3O8 over 5.9 metres including 20.8% U3O8 over 1.5 metres at a vertical depth of 265 metres.

Skyharbour has option agreements with Orano Canada Inc. and Azincourt Energy whereby Orano and Azincourt can earn in up to 70% of the Preston Project through a combined $9,800,000 in total exploration expenditures, as well as $1,700,000 in total cash payments and Azincourt shares. Preston is a large, geologically prospective property proximal to Fission Uranium’s Triple R deposit as well as NexGen Energy’s Arrow deposit.

The Company owns a 100% interest in the South Falcon Uranium Project on the eastern perimeter of the Basin which contains a NI 43-101 inferred resource totaling 7.0 million pounds of U3O8 at 0.03% and 5.3 million pounds of ThO2 at 0.023%. Skyharbour has signed a Definitive Agreement with Australian company Pitchblende Energy, which is being acquired by ASX-listed Valor Resources, on the North Falcon Uranium Project whereby Pitchblende can earn-in 80% of the project through $3,500,000 in total exploration expenditures, $475,000 in total cash payments over three years and an initial share issuance.

Skyharbour’s goal is to maximize shareholder value through new mineral discoveries, committed long-term partnerships, and the advancement of exploration projects in geopolitically favourable jurisdictions

Skyharbour’s Uranium Project Map in the Athabasca Basin:

http://skyharbourltd.com/_resources/maps/SYH-Athabasca-Map.pdf

To find out more about Skyharbour Resources Ltd. (TSX-V: SYH) visit the Company’s website at www.skyharbourltd.com.

SKYHARBOUR RESOURCES LTD.

“Jordan Trimble”
_____________________
                                        
Jordan Trimble
President and CEO

For further information contact myself or:
Spencer Coulter
Corporate Communications
Skyharbour Resources Ltd.
Telephone: 604-687-3800
Toll Free: 800-567-8181
Facsimile: 604-687-3119
Email: [email protected]

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

This release includes certain statements that may be deemed to be “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information. 



Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna’s Vaccine Against COVID-19 in the United States

Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna’s Vaccine Against COVID-19 in the United States

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for the Company’s COVID-19 vaccine candidate, mRNA-1273. 20 VRBPAC members recommended for EUA, 0 members voted against, and 1 abstained.

“We were grateful for the opportunity to present the clinical data package for our mRNA vaccine against COVID-19 to the FDA’s advisory committee today. We thank the committee for their review and for their positive recommendation in support of Emergency Use Authorization,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We have been working with the U.S. Centers for Disease Control and Prevention and Operation Warp Speed to prepare for the distribution of mRNA-1273, if the FDA chooses to grant an Emergency Use Authorization. We look forward to getting our vaccine to people in the U.S. to help address this ongoing public health emergency.”

The VRBPAC based its recommendation on the totality of scientific evidence shared by the Company, including a data analysis from the pivotal Phase 3 clinical study announced on November 30. The primary efficacy analysis conducted on 196 cases indicated a vaccine efficacy rate of 94.1%. The most common solicited adverse reactions (ARs) after the two-dose series included injection site pain (88.2%), erythema (8.6%), swelling (12.2%), and ipsilateral lymphadenopathy (14.2%). While the majority of these ARs were grade 1 (mild) or grade 2 (moderate), there was a higher occurrence of grade 3 (severe) reactions in the mRNA-1273 group and after the second injection. The majority of local solicited ARs occurred within the first one to two days after injection and generally persisted for a median of one to two days. Safety data continue to accrue, and the study continues to be monitored by an independent Data Safety Monitoring Board (DSMB) appointed by the National Institutes of Health (NIH). All participants in the COVE study will be monitored for two years after their second dose to assess long-term protection and safety.

The Phase 3 study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

FDA advisory committees provide non-binding recommendations. The FDA will take the VRBPAC’s recommendation into consideration in making a final decision on approval or authorization. Under an EUA, the FDA has the authority to allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions during a declared public health emergency when there are no adequate, approved, and available alternatives.

Shipping and Temperature Update

Also presented at today’s VRBPAC meeting, Moderna has expanded the handling guidance for mRNA-1273 to include local transport under controlled conditions in a liquid state at 2-8°C (36° to 46°F). In some cases, this may be the only practical means of distribution from clinics and for remote locations. This important update will help facilitate distribution to the final site of administration. Recognizing that shipping and handling of product can be a barrier to vaccination, Moderna remains committed to supporting efficient distribution. Moderna previously announced that mRNA-1273 remains stable at standard refrigerator temperatures of 2° to 8°C (36° to 46°F) for 30 days.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Company’s development of a potential vaccine against the novel coronavirus, the potential for mRNA-1273 to prevent COVID-19 disease and slow the spread of SARS-CoV-2, the safety profile for mRNA-1273, the potential Emergency Use Authorization for mRNA-1273 by the FDA, ongoing safety monitoring under the COVE Study, and the conditions under which mRNA-1273 can be shipped, stored and administered. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of mRNA-1273 observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for mRNA-1273; whether and when any biologics license applications and/or emergency use authorization applications may be filed and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

Moderna

Media:

Colleen Hussey

Director, Corporate Communications

617-335-1374

[email protected]

Investors:

Lavina Talukdar

Head of Investor Relations

617-209-5834

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Medical Supplies Biotechnology FDA Health Pharmaceutical Transport Research Infectious Diseases Logistics/Supply Chain Management Science Clinical Trials

MEDIA:

Logo
Logo

Health Coalition Disappointed with Ford Government’s Staffing Report Announcement: No Recruitment Drive Announced, Timelines for Staffing Improvements Mean Slight Improvements Year After Next

TORONTO, Dec. 17, 2020 (GLOBE NEWSWIRE) — As more and more long-term care homes fall into dire staffing crises, the Ontario Health Coalition expressed its anger and disappointment with the government’s staffing report released today.

“We expected that they would launch a recruitment drive right now because long-term care is in the worst crisis it has ever been in. Instead, we got a report that is tone deaf and has no sense of urgency. It is full of buzzwords and reannouncements and includes timeline that is too late to make any difference in the lifetimes of the people who are living in the homes now,” said Natalie Mehra, executive director.

“In contrast, the province of Quebec launched a central recruitment drive, hired 10,000 PSWs, paid them for training, fast tracked the training and got them into long-term care homes in time for the second wave,” said Ms. Mehra noting that Quebec accomplished all of this between June 1 and October. “This shows what a government that is actually committed to saving lives and providing even basic care to keep people alive and safe does. Compare what Ontario is doing. It is scandalous.”

The concrete items announced are as follows:

  • Reannouncement of the 3,700 staff (across all health care) that was supposed to start in September. No evidence that this is actually happening.
  • Reannouncement of the new beds and money for them. (Note: more beds with existing staff will actually make staffing and care levels per resident worse not better.)
  • Adoption of for-profit’s language of “continuous quality improvement” echoing the language of the for-profit long-term care lobby. This is a euphemism for not having comprehensive surprise inspections, enforcement and accountability, penalties for negligent home operators.
  • This is new: the Ford government says that they will spend “up to” $1.9 billion by 2024-25 to improve staffing. We are not sure why the words “up to” are included.
  • By the end of 2021 -22 they would have 15 mins more hands-on direct care. This is the earliest date for which they have any commitment to improved care. Bottom line: it means that by the April after next, there will be 15 minutes more daily hands-on direct care (RN, RPN, PSW).
  • By the end of 2022-23 another 15 minutes of daily hands-on direct care.
  • They have back-end loaded it – the larger increases are in year 3 (25 mins) and year 4 (20 mins).
  • Thus, by the end of four years from now, and two years after the next provincial election (which is well beyond the average life-expectancy in long-term care) residents would finally get to 4-hours of care per resident per day.

There is no information on when the government will actually start any serious recruitment. No word on improving full-time work. No word on improving wages and working conditions. “If we sound frustrated, it is because we are. Without any exaggeration thousands of residents are suffering, they are dying. This report reads like a delay tactic, not like any serious commitment to address the critical shortfalls of care that are happening right now,” Ms. Mehra concluded.

For more information: Natalie Mehra, executive director (416) 230-6402.



ROSEN, A GLOBAL AND LEADING LAW FIRM, Continues to Investigate Securities Claims Against Huazhu Group Limited – HTHT

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Huazhu Group Limited (NASDAQ: HTHT) resulting from allegations that Huazhu may have issued materially misleading business information to the investing public.

On September 21, 2020, Bonitas Research issued a report on the Company which alleged that Huazhu “lied about the ownership of its hotel portfolio to produce fake financials.” The report also stated that Bonitas’ fieldwork “confirmed that Huazhu secretly supported operating costs of franchisee hotels owned by undisclosed current Huazhu employees & other undisclosed related parties (‘off-book hotels’).” Bonitas further asserted that it “believe[s] that Huazhu concealed operating expenses using undisclosed related party transactions to artificially inflate Huazhu’s reported profits[,]” and that it “calculate[s] that Huazhu’s fake profits manifested as RMB 2 billion (US$ 300 million) of fake PP&E on its CYE’19 balance sheet.”

On this news, Huazhu’s American Depositary Share (“ADS”) price fell $1.54, or over 3%, to close at $40.48 per ADS on September 21, 2020, thereby injuring investors.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Huazhu’s investors. If you purchased ADSs of Huazhu, please visit the firm’s website at http://www.rosenlegal.com/cases-register-1949.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com



Atlas Crest Investment Corp. Announces Appointment of Todd Lemkin to the Board of Directors

Atlas Crest Investment Corp. Announces Appointment of Todd Lemkin to the Board of Directors

Announces Class A Common Stock and Warrants to Commence Trading Separately

NEW YORK–(BUSINESS WIRE)–
Atlas Crest Investment Corp. (NYSE: ACIC.U) today announced the appointment of Todd Lemkin, currently a Partner and Chief Investment Officer of Canyon Partners, LLC, a global alternative asset management firm, as an independent member of its Board of Directors. Mr. Lemkin’s term will begin on December 18, 2020.

Michael Spellacy, CEO of Atlas Crest, said, “We are delighted to add a professional of Todd’s caliber to our Board given his years of experience investing across a broad range of sectors, his international perspectives and financial structuring expertise.”

Mr. Lemkin directs and manages the efforts of Canyon Partners’ portfolio team to develop, analyze, and implement investment ideas across the firm’s global platform. He has extensive investment expertise across the cable, media, telecom, satellite, industrials, real estate, gaming and packaging sectors. Mr. Lemkin has also previously focused on Canyon’s European investment effort and the firm’s London office. Prior to joining Canyon in 2003, Mr. Lemkin was with Scoggin Capital Management in New York, where he focused on analyzing securities of distressed and bankrupt companies.

Atlas Crest also announced that the holders of the company’s units may elect to separately trade the Class A common stock and warrants underlying the units commencing on December 18, 2020. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Those units not separated will continue to trade on the New York Stock Exchange under the symbol ACIC.U and the Class A common stock and the warrants are expected to trade under the symbols ACIC and ACIC WS respectively.

The units were initially offered by the Company in an underwritten offering.

A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission on October 27, 2020.

About Atlas Crest

Atlas Crest Investment Corp. is a special purpose acquisition company formed for the purpose of effecting a merger, stock purchase or similar business combination with one or more businesses. The Company is sponsored by an affiliate of Moelis & Company, a leading global financial advisor to corporate executives, boards, entrepreneurs, financial sponsors and governments. The management team is led by Ken Moelis, as Chairman, and Michael Spellacy, as Chief Executive Officer, both of whom have had careers centered around identifying, evaluating and implementing organic and inorganic transformational growth and value creation initiatives across a broad range of industries. While the Company intends to evaluate opportunities in many sectors, it believes the diverse experience and extensive relationship network of its management team, board and sponsor will drive particularly attractive investment opportunities in certain high growth sectors including media, online gaming/sports betting, fintech/payments, healthcare, business services and disruptive consumer.

For more information, please visit www.atlascrestcorp.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

Taylor Rettig

Atlas Crest

[email protected]

Tel: (860) 508.5086

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Tiffany & Co. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations

Tiffany & Co. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations

NEW YORK–(BUSINESS WIRE)–
Tiffany & Co. (NYSE: TIF) (the “Company”) announced today that holders of a majority in aggregate principal amount of its outstanding $300,000,000 4.900% senior notes due October 1, 2044 (the “2044 Notes”) have delivered valid consents (the “2044Requisite Consents”) in connection with the Company’s proposed amendments described in the Statement (as defined below) for such 2044 Notes.

The Company previously announced on December 15, 2020 that holders of a majority in aggregate principal amount of its outstanding $250,000,000 3.800% senior notes due October 1, 2024 (the “2024 Notes” and together with the 2044 Notes, the “Affected Notes”) had delivered valid consents (the “2024Requisite Consents” and together with the 2044 Requisite Consents, the “Requisite Consents”) in respect of the proposed amendments described in the Statement for such 2024 Notes. The consent solicitations expired at 5:00 p.m., New York City time, on December 14, 2020 for the 2024 Notes and at 5:00 p.m., New York City time, on December 17, 2020 for the 2044 Notes. As a result, all revocation rights in respect of the Affected Notes have been terminated. The terms and conditions of the proposed amendments in respect of the Affected Notes (the “Amendments”) are set forth in the consent solicitation statement dated December 8, 2020 (the “Statement”) previously provided by the Company to the holders of the Affected Notes.

The Company will, subject to (i) the satisfaction or waiver of all terms and conditions to the consent solicitations for a series of Affected Notes described in the Statement and (ii) the closing of the Merger (as defined below), promptly cause to be paid to each holder of a series of Affected Notes who has delivered (and did not revoke) a valid consent in favor of the Amendments prior to the applicable expiration date a cash payment of $1.50 for each $1,000 principal amount of that series of Affected Notes in respect of which such consent has been delivered (and was not revoked), subject to applicable withholding, if any (the “Consent Fee”).

As previously announced, on October 28, 2020, the Company, LVMH Moët Hennessy-Louis Vuitton SE (“LVMH”), Breakfast Holdings Acquisition Corp. and Breakfast Acquisition Corp. (“Merger Sub”), entered into an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”) which provides for, among other things, the acquisition by LVMH of the Company through the merger of Merger Sub with and into the Company (the “Merger”), with the Company continuing as the surviving corporation in the Merger and a wholly-owned indirect subsidiary of LVMH. Subject to the terms of the Merger Agreement and its approval by the Company’s stockholders, the Merger is expected to be completed early in the calendar year 2021.

Following receipt of the Requisite Consents, the Company and the Trustee executed on December 17, 2020 a supplemental indenture incorporating the Amendments into the indenture governing the Affected Notes, dated as September 25, 2014 between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), as supplemented from time to time (the “Indenture”). The Amendments provide that if the Merger is completed, LVMH may elect to provide an unconditional guarantee (the “LVMH Guarantee”) of the Company’s payment obligations with respect to the Affected Notes and any other notes issued from time to time under the Indenture. However, even if the Merger is consummated, LVMH has no obligation to provide any guarantee and there can be no assurance that LVMH will do so. If and for so long as LVMH provides the LVMH Guarantee, LVMH will provide English translations of its periodic and current reporting (under applicable French law) in lieu of the Company’s existing periodic and current reporting obligations, which reporting obligations will not be applicable at any time and for any period during which the LVMH Guarantee is in force.

Questions regarding the consent solicitations may be directed to:

MUFG Securities Americas Inc., Attention: Liability Management at +1 (212) 405-7440 (collect), +1 (877) 744-4532 (toll-free) or +44 20 7577 4048/4218

Citigroup Global Markets Inc., Attention: Liability Management Group at +1 (212) 723-6106 (collect) or +1 (800) 558-3754 (toll-free).

This announcement is not an offer to purchase, a solicitation of an offer to purchase, or a solicitation of consents with respect to any securities. The consent solicitations were made solely by the Statement and were subject to the terms and conditions stated therein.

About Tiffany & Co.:

In 1837, Charles Lewis Tiffany founded his company in New York City where his store was soon acclaimed as the palace of jewels for its exceptional gemstones. Since then, TIFFANY & CO. has become synonymous with elegance, innovative design, fine craftsmanship and creative excellence. During the 20th century fame thrived worldwide with store network expansion and continuous cultural relevance, as exemplified by Truman Capote’s Breakfast at Tiffany’s and the film starring Audrey Hepburn.

Today, with more than 14,000 employees, TIFFANY & CO. and its subsidiaries design, manufacture and market jewelry, watches and luxury accessories – including more than 5,000 skilled artisans who cut diamonds and craft jewelry in the Company’s workshops, realizing its commitment to superlative quality. TIFFANY & CO. has a long-standing commitment to conducting its business responsibly, sustaining the natural environment, prioritizing diversity and inclusion, and positively impacting the communities in which we operate.

Additional Information and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed acquisition of the Company by LVMH pursuant to the Merger Agreement. In connection with the proposed acquisition, the Company filed a definitive proxy statement on Schedule 14A with the U.S. Securities and Exchange Commission (the “SEC”), and mailed the definitive proxy statement and a proxy card to each stockholder entitled to vote at the special meeting relating to the proposed acquisition. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ CAREFULLY ALL RELEVANT DOCUMENTS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED WITH THE SEC, INCLUDING THE COMPANY’S DEFINITIVE PROXY STATEMENT, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSED ACQUISITION. Investors and security holders are able to obtain copies of the definitive proxy statement and other documents filed with the SEC (when available) free of charge at the SEC’s website at www.sec.gov or at the Company’s website at investor.tiffany.com/financial-information or by writing to the Corporate Secretary at 200 Fifth Avenue, New York, New York 10010, Attn: Corporate Secretary (Legal Department).

Participants in Solicitation

The Company and its directors, executive officers and certain of its employees may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in respect of the proposed acquisition. Information about the directors and executive officers of the Company is set forth in its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on April 20, 2020, and the definitive proxy statement filed with the SEC in connection with the proposed acquisition on November 27, 2020. Other information regarding the participants in the proxy solicitations in connection with the proposed acquisition, and a description of any interests that they have in the proposed acquisition, by security holdings or otherwise, may be contained in other relevant materials to be filed with the SEC regarding the proposed acquisition when they become available. These documents may be obtained for free at the SEC’s website at www.sec.gov, or by writing to the Corporate Secretary at 200 Fifth Avenue, New York, New York, 10010, Attn: Corporate Secretary (Legal Department).

Forward-Looking Statements

Certain statements in this communication including, without limitation, statements relating to the Merger and conditions to closing of the Merger, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, each as amended. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the Merger (and the anticipated benefits thereof) and about the future plans, assumptions and expectations for the Company’s business and its results. Forward-looking statements provide current expectations of future events and include any statement that does not directly relate to any historical or current fact. Words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “projects,” “may,” “will,” or other similar expressions may identify such forward-looking statements.

These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those discussed in forward-looking statements, including, as a result of factors, risks and uncertainties over which the Company has no control. The inclusion of such statements should not be regarded as a representation that any plans, estimates or expectations will be achieved. You should not place undue reliance on such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from such plans, estimates or expectations include, but are not limited to, the following: (i) conditions to the completion of the Merger, including stockholder approval of the merger proposal, may not be satisfied or the regulatory approvals or waivers required for the Merger may not be obtained or maintained, in each case, on the terms expected or on the anticipated schedule; (ii) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement between the parties to the merger or affect the ability of the parties to recognize the benefits of the Merger; (iii) the effect of the announcement or pendency of the Merger on the Company’s business relationships, operating results, and business generally; (iv) risks that the Merger disrupts the Company’s current plans and operations and potential difficulties in the Company’s employee retention; (v) risks that the Merger may divert management’s attention from the Company’s ongoing business operations; (vi) potential litigation that may be instituted against the Company or its directors or officers related to the Merger or the Merger Agreement between the parties to the merger and any adverse outcome of any such potential litigation; (vii) the amount and timing of the costs, fees, expenses and other charges related to the Merger, including in the event of any unexpected delays; (viii) other risks to consummation of the Merger, including the risk that the Merger will not be consummated within the expected time period, or at all, which may affect the Company’s business and the price of the common stock of the Company; (ix) any adverse effects on the Company by other general industry, economic, business and/or competitive factors; (x) the COVID-19 pandemic, including the duration and scope thereof, the availability of a vaccine or cure that mitigates the effect of the virus, the potential for additional waves of outbreaks and changes in financial, business, travel and tourism, consumer discretionary spending and other general consumer behaviors, political, public health and other conditions, circumstances, requirements and practices resulting therefrom; (xi) protest activity in the U.S.; and (xii) such other factors as are set forth in the Company’s periodic public filings with the SEC, including but not limited to those described under the headings “Risk Factors” and “Forward Looking Statements” in the Company’s Form 10-Q for the fiscal quarter ended October 31, 2020, its Form 10-K for the fiscal year ended January 31, 2020, and in its other filings made with the SEC from time to time, which are available via the SEC’s website at www.sec.gov. The consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the Company’s financial condition, results of operations, credit rating or liquidity or stock price. These risks, as well as other risks associated with the Merger, are more fully discussed in the definitive proxy statement on Schedule 14A, which was filed with the SEC on November 27, 2020, in connection with the Merger. In addition, there can be no assurance that the Merger will be completed, or if it is completed, that it will close within the anticipated time period, or that the expected benefits of the Merger will be realized.

Forward-looking statements reflect the views and assumptions of management as of the date of this communication with respect to future events. The Company does not undertake, and hereby disclaims, any obligation, unless required to do so by applicable securities laws, to update any forward-looking statements as a result of new information, future events or other factors. The inclusion of any statement in this communication does not constitute an admission by the Company or any other person that the events or circumstances described in such statement are material.

Jason Wong

(973) 254-7612

[email protected]

 

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Fashion Professional Services Retail Luxury Specialty Finance

MEDIA:

Logo
Logo

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of TPG Pace Beneficial Finance Corp. Merger

WILMINGTON, Del., Dec. 17, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating TPG Pace Beneficial Finance Corp. (“TPG”) (NYSE: TPGY) regarding possible breaches of fiduciary duties and other violations of law related to TPG’s agreement to acquire EV Charged B.V.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-tpg-pace-beneficial-finance-corp.

You may contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:         

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com